3,020
Views
29
CrossRef citations to date
0
Altmetric
Original Research

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

ORCID Icon, ORCID Icon, , , , , , , & show all
Pages 727-735 | Received 27 Mar 2018, Accepted 23 May 2018, Published online: 06 Jun 2018